GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Cost of Goods Sold

Lee's Pharmaceutical Holdings (HKSE:00950) Cost of Goods Sold : HK$647 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Cost of Goods Sold?

Lee's Pharmaceutical Holdings's cost of goods sold for the six months ended in Dec. 2024 was HK$339 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2024 was HK$647 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lee's Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2024 was 54.31%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Lee's Pharmaceutical Holdings's Inventory Turnover for the six months ended in Dec. 2024 was 1.32.


Lee's Pharmaceutical Holdings Cost of Goods Sold Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Cost of Goods Sold Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 435.65 459.87 462.39 501.72 646.61

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.71 227.85 273.88 307.75 338.86

Lee's Pharmaceutical Holdings Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$647 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (HKSE:00950) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lee's Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(741.624 - 338.864) / 741.624
=54.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Lee's Pharmaceutical Holdings's Inventory Turnover for the six months ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Lee's Pharmaceutical Holdings Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Executives
Leelalertsuphakun Wanee 2101 Beneficial owner
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Huang Zuie-chin 2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky 2202 Interest of your spouse
Li Xiaoyi 2101 Beneficial owner
Lee Siu Fong 2101 Beneficial owner
Ubs Group Ag 2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p. 2101 Beneficial owner
Panacea Innovation Limited 2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Apta Finance Sa 2201 Interest of corporation controlled by you
Qualister Sa 2101 Beneficial owner
Paponi Claudia 2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines